# Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

> **NCT00006019** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Leukemia
- Lung Cancer
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Prostate Cancer

## Interventions

- **DRUG:** azacitidine
- **DRUG:** sodium phenylbutyrate

## Key facts

- **NCT ID:** NCT00006019
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006019, "Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00006019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*